Year archive

Zelluna ASA — 2024 filings

All 67 regulatory filings released by Zelluna ASA (ULTI) in 2024, sourced directly from the official regulator.

67 Filings

2024 Period

2024 filings (67)

Filing	Released	Lang
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update Interim / Quarterly Report Q3 2024	2024-11-06	English
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update Interim / Quarterly Report Q3 2024	2024-11-06	English
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update Earnings Release Q3 2024	2024-11-06	English
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation Report Publication Announcement	2024-10-31	English
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv Regulatory Filings	2024-10-25	English
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer Regulatory Filings	2024-09-11	English
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 Legal Proceedings Report	2024-09-08	English
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update Investor Presentation Q2 2024	2024-08-21	English
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update Interim / Quarterly Report Q2 2024	2024-08-21	English
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update Earnings Release Q2 2024	2024-08-21	English
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation Report Publication Announcement	2024-08-15	English
Ultimovacs Announces Notice of Resignation from Deputy Board Member Board/Management Information	2024-08-07	English
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer Regulatory Filings	2024-08-05	English
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 Regulatory Filings	2024-08-01	English
Ultimovacs ASA announces revised terms of the employee share option program Remuneration Information	2024-06-24	English
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab Regulatory Filings	2024-06-11	English
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Report Publication Announcement	2024-06-01	English
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update Earnings Release Q1 2024	2024-05-07	English
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update Interim / Quarterly Report Q1 2024	2024-05-07	English
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update Earnings Release Q1 2024	2024-05-07	English
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation Report Publication Announcement	2024-04-30	English
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Report Publication Announcement	2024-04-24	English
Ultimovacs ASA - Annual General Meeting held on April 18, 2024 AGM Information	2024-04-18	Norwegian
Ultimovacs ASA - Annual General Meeting held on April 18, 2024 AGM Information	2024-04-18	English
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program Investor Presentation	2024-04-16	English
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program Regulatory Filings	2024-04-16	English
Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting Declaration of Voting Results & Voting Rights Announcements	2024-04-15	English
Ultimovacs - Invitation to Business Update on April 17, 2024 Report Publication Announcement	2024-04-09	English
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 Report Publication Announcement	2024-04-04	English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 Governance Information	2024-03-25	Norwegian
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 Remuneration Information	2024-03-25	English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 Remuneration Information	2024-03-25	English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 Remuneration Information	2024-03-25	English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 Annual Report FY 2023	2024-03-25	English
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 AGM Information	2024-03-25	Norwegian
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 AGM Information	2024-03-25	Norwegian
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 AGM Information	2024-03-25	English
Ultimovacs ASA: Mandatory notification of trade by primary insider Director's Dealing	2024-03-22	Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insider Director's Dealing	2024-03-22	English
Ultimovacs ASA: Annual Report 2023 Annual Report FY 2023	2024-03-21	English
Ultimovacs ASA: Annual Report 2023 Annual Report FY 2023	2024-03-21	English
Ultimovacs ASA: Annual Report 2023 Report Publication Announcement	2024-03-21	English
Ultimovacs ASA: Mandatory notification of trades by primary insider Director's Dealing	2024-03-09	Norwegian
Ultimovacs ASA: Mandatory notification of trades by primary insider Director's Dealing	2024-03-09	English
Ultimovacs ASA: Mandatory notification of trades by primary insider Director's Dealing	2024-03-08	English
Ultimovacs ASA: Mandatory notification of trades by primary insider Director's Dealing	2024-03-08	English
Ultimovacs ASA – Mandatory trade notification and disclosure of holding Director's Dealing	2024-03-08	English
Ultimovacs ASA – Mandatory trade notification and disclosure of holding Major Shareholding Notification	2024-03-08	English
Ultimovacs ASA: Mandatory notification of trade by primary insiders Director's Dealing	2024-03-07	Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insiders Director's Dealing	2024-03-07	Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insiders Director's Dealing	2024-03-07	English
Ultimovacs ASA – Disclosure of shareholding Director's Dealing	2024-03-07	English
Ultimovacs ASA – Disclosure of shareholding Declaration of Voting Results & Voting Rights Announcements	2024-03-07	English
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma Earnings Release Q1 2024	2024-03-07	English
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer Regulatory Filings	2024-03-02	English
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma Investor Presentation	2024-02-19	English
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update Investor Presentation	2024-02-14	English
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update Interim / Quarterly Report Q4 2023	2024-02-14	English
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update Earnings Release Q4 2023	2024-02-14	English
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation Report Publication Announcement	2024-02-08	English
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma Regulatory Filings	2024-02-05	English
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024 Regulatory Filings	2024-01-16	English
Ultimovacs ASA: Mandatory notification of trade by primary insider Director's Dealing	2024-01-04	English
Ultimovacs ASA: Mandatory notification of trade by primary insider Director's Dealing	2024-01-04	English
Ultimovacs ASA: Mandatory notification of trade by primary insider Director's Dealing	2024-01-02	English
Ultimovacs ASA: Mandatory notification of trade by primary insider Director's Dealing	2024-01-02	English
Ultimovacs ASA: Mandatory notification of trade by primary insider Director's Dealing	2024-01-02	English

Filings by year

2026 39 filings
2025 80 filings
2024 67 filings
2023 61 filings
2022 68 filings
2021 80 filings
2020 55 filings
2019 33 filings